Irsamla (Vortioxetine Hydrobromide)

Vortioxetine acts as a serotonin modulator and stimulator. It blocks several serotonin receptors, stimulates the 5‑HT1A receptor, and inhibits the serotonin transporter, resulting in increased serotonin availability and balanced neurotransmission across multiple pathways.

The appropriate dose of Irsamla is determined by the prescribing healthcare professional based on the individual’s clinical condition, response, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for vortioxetine in pregnancy and lactation are limited. The prescriber will weigh potential benefits against possible risks to the fetus or infant before deciding to use Irsamla in these populations.

To request Irsamla, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irsamla (vortioxetine) differs from traditional SSRIs by also modulating multiple serotonin receptors, which may offer benefits for cognition and fewer sexual side effects. However, individual response varies, and the choice of antidepressant should be guided by the prescriber based on patient profile and tolerability.

Store Irsamla at ambient temperature, below 25 °C, in the original packaging. Protect the tablets from moisture, heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Irsamla is taken orally as a tablet, usually once daily. It can be swallowed with or without food, but patients should follow the specific instructions provided by their healthcare professional.

Serious risks include serotonin syndrome, emergence of suicidal thoughts or behaviors, severe hyponatremia, and allergic reactions such as rash or angioedema. Patients should seek immediate medical attention if they experience any of these symptoms.

Irsamla should not be used by individuals currently taking monoamine oxidase inhibitors (MAOIs) or those with known hypersensitivity to vortioxetine or any tablet excipients. Caution is also advised in patients with severe hepatic impairment or a history of serotonin syndrome.